- Q2 2023 Biosyent Inc Earnings Call TranscriptAug 22, 2023$5.54Earnings
- Q1 2023 Biosyent Inc Earnings Presentation TranscriptMay 26, 2023
- Q4 2022 Biosyent Inc Earnings Call TranscriptMar 21, 2023$5.32Earnings
- Biosyent Inc at Issuer Direct Planet MicroCap Showcase (Virtual) TranscriptDec 07, 2022
- Q3 2022 Biosyent Inc Earnings Presentation TranscriptNov 16, 2022
- Q2 2022 Biosyent Inc Earnings Presentation TranscriptAug 23, 2022
- Q1 2022 Biosyent Inc Earnings Presentation TranscriptMay 18, 2022
- Q4 2021 Biosyent Inc Earnings Presentation TranscriptMar 09, 2022
- Q3 2021 Biosyent Inc Earnings Call TranscriptNov 18, 2021$5.71Earnings
- Q2 2021 Biosyent Inc Earnings Call TranscriptAug 25, 2021$6.12 (-2.99%)Earnings
- Q1 2021 Biosyent Inc Earnings Call TranscriptMay 27, 2021$6.19Earnings
- Biosyent Inc Annual Shareholders Meeting TranscriptMay 26, 2021
- Q4 2020 Biosyent Inc Earnings Call TranscriptMar 17, 2021$5.76 (-1.71%)Earnings
- Q3 2020 Biosyent Inc Earnings Call TranscriptNov 26, 2020Earnings
- Q2 2020 Biosyent Inc Earnings Call TranscriptAug 26, 2020$5.24 (+0.13%)Earnings
- Q1 2020 Biosyent Inc Earnings Presentation TranscriptMay 28, 2020
- Q3 2019 Biosyent Inc Earnings Call TranscriptNov 20, 2019$4.99 (+13.41%)Earnings
- Q2 2019 Biosyent Inc Earnings Call TranscriptAug 23, 2019$4.52 (-9.60%)Earnings
- Q1 2019 Biosyent Inc Earnings Call TranscriptMay 29, 2019$5.84 (-3.15%)Earnings
- Q4 2018 Biosyent Inc Earnings Call TranscriptMar 20, 2019$6.2 (+0.81%)Earnings
Q3 2021 Biosyent Inc Earnings Call Transcript
© -
Hello, and welcome to the BioSyent Inc. Q3 and YTD 2021 results presentation for the 9 months ended September 30. My name is René Goehrum, and I'm the President and CEO of the company.
I'm going to start today's presentation with a look at our sales, EBITDA and net income after tax for the 3 months ended September 30 of '21.
As you can see, our sales were just below $6.7 million in the quarter. That was an increase of 16% versus the year ago, driven by our Canadian Pharmaceutical business, up 17% measured in dollars, and we did not ship to any International Pharmaceutical customers in the quarter. I've got some more comments on that in subsequent slides. And our Legacy Business was down 5% in the quarter.
Our EBITDA was just under $2.3 million, representing a 64% increase to the year ago, and our net profit of $1.72 million was up 80% to the year ago. It represented our 45th consecutive profitable quarter and our net margin after tax of 26% represented a high watermark in quite some period of time.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)